PRINCETON, N.J. — Biotechnology company Signum Biosciences has entered a collaborative agreement with GlaxoSmithKline whereby GSK will receive the exclusive right to Signum's proprietary phosphatase screening technology.
GSK and Signum said the companies "will undertake a broad research and development collaboration to screen and identify phosphoprotein phosphatase 2A (PP2A) targeted compounds, including those bridging the link between PP2A methylation and tau hyperphosphorylation." As part of the agreement, Signum will be provided research support and milestone payments as GSK forges ahead with its research and development activities in neurosciences.
"GSK is an ideal partner for Signum," Signum president Maxwell Stock said. "We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies. We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."